Protalix BioTherapeutics
PLX
PLX
44 hedge funds and large institutions have $160M invested in Protalix BioTherapeutics in 2014 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
2% less funds holding
Funds holding: 45 → 44 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
96% less call options, than puts
Call options by funds: $152K | Put options by funds: $4.18M
Holders
44
Holding in Top 10
1
Calls
$152K
Puts
$4.18M
Top Buyers
| 1 | +$627K | |
| 2 | +$501K | |
| 3 | +$334K | |
| 4 |
Morgan Stanley
New York
|
+$237K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$135K |
Top Sellers
| 1 | -$2.72M | |
| 2 | -$1.12M | |
| 3 | -$939K | |
| 4 |
FRM
Fore Research & Management
New York
|
-$617K |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$402K |